![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GTF3C6 |
Gene summary for GTF3C6 |
![]() |
Gene information | Species | Human | Gene symbol | GTF3C6 | Gene ID | 112495 |
Gene name | general transcription factor IIIC subunit 6 | |
Gene Alias | C6orf51 | |
Cytomap | 6q21 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q969F1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
112495 | GTF3C6 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.39e-06 | 3.38e-01 | -0.1808 |
112495 | GTF3C6 | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.11e-04 | 2.92e-01 | -0.0811 |
112495 | GTF3C6 | HTA11_78_2000001011 | Human | Colorectum | AD | 6.79e-03 | 2.14e-01 | -0.1088 |
112495 | GTF3C6 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.33e-16 | 3.82e-01 | -0.1954 |
112495 | GTF3C6 | HTA11_83_2000001011 | Human | Colorectum | SER | 2.92e-02 | 3.35e-01 | -0.1526 |
112495 | GTF3C6 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.53e-10 | 2.88e-01 | -0.1464 |
112495 | GTF3C6 | HTA11_866_2000001011 | Human | Colorectum | AD | 7.88e-03 | 1.52e-01 | -0.1001 |
112495 | GTF3C6 | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.19e-09 | 3.50e-01 | -0.059 |
112495 | GTF3C6 | HTA11_5212_2000001011 | Human | Colorectum | AD | 2.47e-02 | 3.34e-01 | -0.2061 |
112495 | GTF3C6 | HTA11_7862_2000001011 | Human | Colorectum | AD | 3.68e-02 | 2.56e-01 | -0.0179 |
112495 | GTF3C6 | HTA11_866_3004761011 | Human | Colorectum | AD | 5.46e-08 | 3.07e-01 | 0.096 |
112495 | GTF3C6 | HTA11_7663_2000001011 | Human | Colorectum | SER | 1.26e-02 | 3.35e-01 | 0.0131 |
112495 | GTF3C6 | HTA11_6801_2000001011 | Human | Colorectum | SER | 2.39e-04 | 5.73e-01 | 0.0171 |
112495 | GTF3C6 | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.17e-05 | 2.13e-01 | 0.0674 |
112495 | GTF3C6 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.81e-19 | 3.86e-01 | 0.294 |
112495 | GTF3C6 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.96e-02 | 5.36e-01 | 0.3487 |
112495 | GTF3C6 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.24e-04 | 3.11e-01 | 0.281 |
112495 | GTF3C6 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 5.07e-03 | 1.73e-01 | 0.3859 |
112495 | GTF3C6 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 7.13e-06 | 2.22e-01 | 0.3005 |
112495 | GTF3C6 | AEH-subject1 | Human | Endometrium | AEH | 3.07e-19 | -3.89e-01 | -0.3059 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00063833 | Esophagus | ESCC | transcription by RNA polymerase III | 41/8552 | 46/18723 | 7.69e-10 | 1.90e-08 | 41 |
GO:00987812 | Esophagus | ESCC | ncRNA transcription | 45/8552 | 56/18723 | 1.05e-07 | 1.72e-06 | 45 |
GO:00093032 | Esophagus | ESCC | rRNA transcription | 28/8552 | 34/18723 | 1.21e-05 | 1.12e-04 | 28 |
GO:0009303 | Liver | HCC | rRNA transcription | 25/7958 | 34/18723 | 2.42e-04 | 1.81e-03 | 25 |
GO:0006383 | Liver | HCC | transcription by RNA polymerase III | 31/7958 | 46/18723 | 5.67e-04 | 3.61e-03 | 31 |
GO:0098781 | Liver | HCC | ncRNA transcription | 33/7958 | 56/18723 | 9.64e-03 | 3.63e-02 | 33 |
GO:00063832 | Oral cavity | OSCC | transcription by RNA polymerase III | 34/7305 | 46/18723 | 1.61e-06 | 2.11e-05 | 34 |
GO:00987811 | Oral cavity | OSCC | ncRNA transcription | 38/7305 | 56/18723 | 1.15e-05 | 1.18e-04 | 38 |
GO:00093031 | Oral cavity | OSCC | rRNA transcription | 24/7305 | 34/18723 | 1.89e-04 | 1.28e-03 | 24 |
GO:00063831 | Oral cavity | LP | transcription by RNA polymerase III | 20/4623 | 46/18723 | 4.03e-03 | 2.61e-02 | 20 |
GO:00987813 | Skin | cSCC | ncRNA transcription | 28/4864 | 56/18723 | 9.93e-05 | 9.22e-04 | 28 |
GO:00093033 | Skin | cSCC | rRNA transcription | 19/4864 | 34/18723 | 2.03e-04 | 1.69e-03 | 19 |
GO:00063834 | Skin | cSCC | transcription by RNA polymerase III | 20/4864 | 46/18723 | 7.44e-03 | 3.50e-02 | 20 |
GO:00987814 | Thyroid | PTC | ncRNA transcription | 27/5968 | 56/18723 | 7.77e-03 | 3.29e-02 | 27 |
GO:00063835 | Thyroid | PTC | transcription by RNA polymerase III | 23/5968 | 46/18723 | 7.89e-03 | 3.33e-02 | 23 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GTF3C6 | SNV | Missense_Mutation | rs748520635 | c.407N>A | p.Arg136Gln | p.R136Q | Q969F1 | protein_coding | deleterious(0) | possibly_damaging(0.859) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
GTF3C6 | SNV | Missense_Mutation | novel | c.339G>T | p.Lys113Asn | p.K113N | Q969F1 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
GTF3C6 | SNV | Missense_Mutation | rs748520635 | c.407G>A | p.Arg136Gln | p.R136Q | Q969F1 | protein_coding | deleterious(0) | possibly_damaging(0.859) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GTF3C6 | SNV | Missense_Mutation | novel | c.145G>C | p.Asp49His | p.D49H | Q969F1 | protein_coding | deleterious(0) | possibly_damaging(0.899) | TCGA-55-A4DF-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
GTF3C6 | SNV | Missense_Mutation | novel | c.461N>T | p.Ala154Val | p.A154V | Q969F1 | protein_coding | tolerated(0.11) | benign(0.003) | TCGA-NC-A5HF-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
GTF3C6 | SNV | Missense_Mutation | novel | c.430C>G | p.Leu144Val | p.L144V | Q969F1 | protein_coding | tolerated(0.21) | benign(0.01) | TCGA-CR-6472-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | paclitaxel | SD |
GTF3C6 | insertion | Frame_Shift_Ins | novel | c.589_590insT | p.Pro198ThrfsTer3 | p.P198Tfs*3 | Q969F1 | protein_coding | TCGA-CV-7435-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
GTF3C6 | SNV | Missense_Mutation | c.501G>T | p.Glu167Asp | p.E167D | Q969F1 | protein_coding | tolerated(0.07) | benign(0.206) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |